Artivion, Inc. (NYSE:AORT) Shares Sold by Royce & Associates LP

Royce & Associates LP trimmed its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 831,000 shares of the company's stock after selling 40,170 shares during the quarter. Royce & Associates LP owned about 1.98% of Artivion worth $23,758,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quarry LP increased its stake in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after acquiring an additional 820 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares in the last quarter. R Squared Ltd acquired a new position in Artivion during the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion during the 4th quarter worth approximately $43,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Artivion in the 4th quarter valued at approximately $78,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AORT. Stifel Nicolaus dropped their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Needham & Company LLC lowered their price target on shares of Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion currently has an average rating of "Buy" and an average price target of $31.40.

Remove Ads

Artivion Price Performance

Artivion stock traded down $0.17 during trading hours on Thursday, hitting $24.21. The stock had a trading volume of 416,218 shares, compared to its average volume of 262,084. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1,210.25 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 1-year low of $19.36 and a 1-year high of $32.33. The stock's fifty day moving average is $28.37 and its two-hundred day moving average is $27.68.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO James P. Mackin sold 42,156 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares of the company's stock, valued at approximately $18,130,617.42. The trade was a 5.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 5,335 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,799 shares of company stock worth $2,356,223 in the last ninety days. Insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.